ACOG Practice Bulletin No. 192: Management of Alloimmunization During Pregnancy

Obstet Gynecol. 2018 Mar;131(3):e82-e90. doi: 10.1097/AOG.0000000000002528.


When any fetal blood group factor inherited from the father is not possessed by the mother, antepartum or intrapartum fetal-maternal bleeding may stimulate an immune reaction in the mother. Maternal immune reactions also can occur from blood product transfusion. The formation of maternal antibodies, or "alloimmunization," may lead to various degrees of transplacental passage of these antibodies into the fetal circulation. Depending on the degree of antigenicity and the amount and type of antibodies involved, this transplacental passage may lead to hemolytic disease in the fetus and neonate. Undiagnosed and untreated, alloimmunization can lead to significant perinatal morbidity and mortality. Advances in Doppler ultrasonography have led to the development of noninvasive methods of management of alloimmunization in pregnant women. Together with more established protocols, Doppler ultrasound evaluation may allow for a more thorough and less invasive workup with fewer risks to the mother and fetus. Prevention of alloimmunization is addressed in another Practice Bulletin ().

Publication types

  • Practice Guideline

MeSH terms

  • Erythroblastosis, Fetal / diagnosis
  • Erythroblastosis, Fetal / etiology
  • Erythroblastosis, Fetal / therapy
  • Female
  • Fetomaternal Transfusion / diagnosis
  • Fetomaternal Transfusion / immunology
  • Fetomaternal Transfusion / therapy
  • Humans
  • Pregnancy
  • Pregnancy Complications, Hematologic / diagnosis*
  • Pregnancy Complications, Hematologic / therapy*
  • Prenatal Care / methods*
  • Rh Isoimmunization / diagnosis*
  • Rh Isoimmunization / therapy*
  • Ultrasonography, Prenatal